TerminatedNot Applicable

Liver Regeneration

Stopped: Poor recruitment

Canada2 participantsStarted 2017-09-12

Plain-language summary

The liver is the only visceral organ with a tremendous capacity to regenerate. We don't yet understand how normal liver regeneration occurs (on a molecular level) or how to distinguish between normal and "abnormal"/neoplastic regeneration. This study will characterize the role of the different liver cell types in the regeneration process and will examine gene expression changes in the various liver cell types.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * willing and able to provide written informed consent * No history of liver disease or dysfunction Exclusion Criteria: * Patients who receive chemotherapy within the 6 weeks prior to their hepatectomy and/or would be started on active chemotherapy within the first 4 weeks post-hepatectomy. * Patients requiring long-term anticoagulation

What they're measuring

Gene expression

Timeframe: week 1 post-resection

Trial details

NCT IDNCT03396705

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-03-19

View on ClinicalTrials.gov More Liver Diseases trials